TP53 and myelodysplastic syndrome: Among 30 unique TP53 intragenic mutations in patients with MDS, 28 (93.3%) localized to the DNA‐binding domain, with only 1 mutation (3.3%) each in the transactivation domain and the proline‐rich domain.